ViiV Healthcare, the specialist HIV company majority owned by GSK (LSE: GSK), today announced the presentation of new ...
Responding to growing pressure, ViiV Healthcare announced steps to widen access to its HIV prevention medicine in low- and ...
GlobalData on MSN9d
ViiV Healthcare to increase annual supply of long-acting HIV PrEPThe announcement marks another important milestone in our efforts to accelerate access to the only long-acting PrEP available ...
With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...
The Indian Patent Office has rejected Viiv Healthcare's patent application for the HIV drug, dolutegravir, after nearly a ...
The survey also found that flexible and virtual appointments, as well as transportation support, were helpful while on ...
ViiV Healthcare sponsored events to address the climbing rates of HIV infections on HBCU campuses and the surrounding Black ...
At Alabama State University's homecoming, ViiV Healthcare partnered with the campus to raise awareness about HIV prevention, ...
ViiV Healthcare’s latest HIV prevention campaign coincided with one of the biggest weekends of the year at Alabama State ...
ViiV Healthcare to triple annual supply of long-acting HIV PrEP for low- and middle-income countries
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the company’s commitment to make at least two million doses of ...
GSK & ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024: London, UK Monday, October 14, 2024, 14:00 Hrs [IST] GSK plc and Vi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback